About PeptideOnline

Our Mission

PeptideOnline exists to bridge the gap between cutting-edge peptide research and the people who need clear, accurate information to make informed decisions about their health.

The peptide therapy landscape changed dramatically in early 2026 when approximately 14 peptides were reclassified from FDA Category 2 back to Category 1, making them legally available through compounding pharmacies again. This regulatory shift created an urgent need for trustworthy, up-to-date educational content — and that's exactly what we provide.

Editorial Standards

Every peptide profile and guide on this site follows a rigorous editorial process:

• Primary source citations — Clinical claims link directly to PubMed, peer-reviewed journals, or government sources
• Regulatory accuracy — Legal status information is verified against current FDA and HHS classifications
• Balanced reporting — We cover both potential benefits and known risks, side effects, and limitations
• No fabricated content — No fake testimonials, no invented data, no AI-generated author personas

Affiliate Transparency

PeptideOnline earns revenue through affiliate partnerships with research peptide suppliers and other health-related services. This financial relationship is always disclosed and never influences our editorial content. We recommend products based on verified quality standards — third-party testing, COA availability, and reliable fulfillment — not commission rates.

For full details, see our Terms of Service and Affiliate Disclosure.

Contact Us

Have questions, corrections, or want to discuss a partnership? Reach out here.